Sionna Therapeutics (SION) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Sionna Therapeutics (SION) over the past year, gaining 1.5% versus a loss of 93.5%. Zentalis Pharmaceuticals is the larger company by market cap ($133.6 million vs $127.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SION | ZNTL |
|---|---|---|
| Share price | $2.83 | $1.36 |
| Market cap | $127.79M | $133.64M |
| 1-day change | -4.88% | 0.00% |
| YTD return | -93.13% | +0.74% |
| 1-year return | -93.53% | +1.49% |
| 5-year return | — | -98.21% |
| EPS (TTM) | $-2.43 | $-1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-75.27M | $-137.06M |
| 52-week high | $54.97 | $6.95 |
| 52-week low | $2.75 | $1.30 |
| Distance from 52-week high | -94.86% | -80.43% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +643.36% | +447.06% |
| Average volume | 1.12M | 1.26M |
| Shares outstanding | 45.24M | 98.27M |
| Employees | 59 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed SION by 95.0 percentage points over the past year.
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
SION vs ZNTL FAQ
Which is bigger, Sionna Therapeutics or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $133.64M compared with $127.79M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, SION or ZNTL?
ZNTL returned +1.49% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Sionna Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.